Tumor resistance to cytotoxic therapeutics coupled with dose-limiting toxicity is a serious
hurdle in the field of medical oncology. In the face of this obstacle, nitric oxide has emerged …

The development of cancer cell resistance to various cytotoxic stimuli continues to be a
major challenge in oncology and novel therapeutic approaches are urgently needed. Nitric …

Resistance to current therapeutic interventions is a major challenge in the treatment of
patients affected by cancer. While nitric oxide (NO) might have proneoplastic properties, it is …

Cancer is not a single disease but it constitutes a large variety of different types that are also
different from each other phenotypically and molecularly. Although the standard treatments …

A blueprint for the ideal anticancer molecule would include most of the properties of nitric
oxide (NO•), but the ability to exploit these characteristics in a therapeutic setting requires a …

Several novel therapeutic strategies are currently being explored for the treatment of tumors
that are refractory to conventional cytotoxic therapies. Further, therapies aimed at the …

Low level nitric oxide (NO) produced by inducible NO synthase (iNOS) in many malignant
tumors is known to play a key role in the survival and proliferation of tumor cells. NO can …

The role of nitric oxide (NO•) as a mediator of cancer phenotype has led researchers to
investigate strategies for manipulating in vivo production and exogenous delivery of this …

Much research over the past two decades has focussed on understanding the complex
interactions of nitric oxide (NO) in both physiological and pathological processes. As with …

The treatment of primary tumors results in an initial response to approved conventional
therapeutics. However, recurrences and malignancies develop as a result of tumors' …